Skip to main content
. 2022 Sep 20;4(1):23–31. doi: 10.34067/KID.0004172022

Table 5.

Solute plasma levels favoring furosemide clearance compared with iGFR (above 90th percentile regression line)

−log(P): Furosemide −log(P): iGFR Compound Protein Binding (%) CoV CLr-to-CrCl Ratio
8.8 6.9 2-[(4-Aminobenzoyl)amino]acetic acid 19 0.3 10.9
7.3 5 1,4-Cyclohexanedicarboxylic acid 15 0.3 2.4
6.6 5.8 Biotin 2 0.3 2.7
6.4 5 3′-Sialyllactose 21 0.3 5.7
5.5 3.5 Phenylacetylglycine 18 0.3 4.3
5.5 2.7 Choline 6 0.2 0.2
5.4 3.8 3-Dehydrocarnitine 11 0.1 11.3
5.1 4.6 2′-O-Methylinosine 4 0.5 0.6
4.6 4 3-Hydroxyanthranilic acid 15 0.3 3.2
4.6 3.2 2-[(4-Aminobenzoyl)amino]acetic acid 8 0.5 21.3
4.2 3.3 N-Isovalerylglycine 24 0.5 10.2
4.1 3.3 Picolinuric acid 37 0.8 47.6
4 3.4 α-Galactosamine-1-phosphate 17 0.2 3.1
4 2.5 Hexanoyl-L-carnitine 30 0.4 1.9
4 3 Pantothenic acid 24 0.6 0.5
3.9 2.9 Glu-Val 15 0.3 1
3.9 3.1 Isomaltose A 18 0.9 3.3
3.9 2.2 N-Acetylmannosamine 12 0.3 0.9
3.7 2.7 4-Hydroxyhippuric acid 25 0.3 3.6
3.5 1.6 N-Acetylneuraminic acid 4 0.4 2.4

Candidate solutes are ordered by the kidney clearance association with furosemide clearance. iGFR, iohexol GFR; CoV, coefficient of variation; CLr-to-CrCl ratio, solute clearance-to-creatinine clearance ratio.